Literature DB >> 28315874

Multiple Drug Hypersensitivity.

Werner J Pichler1, Yuttana Srinoulprasert, James Yun, Oliver Hausmann.   

Abstract

Multiple drug hypersensitivity (MDH) is a syndrome that develops as a consequence of massive T-cell stimulations and is characterized by long-lasting drug hypersensitivity reactions (DHR) to different drugs. The initial symptoms are mostly severe exanthems or drug rash with eosinophilia and systemic symptoms (DRESS). Subsequent symptoms due to another drug often appear in the following weeks, overlapping with the first DHR, or months to years later after resolution of the initial presentation. The second DHR includes exanthema, erythroderma, DRESS, Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), hepatitis, and agranulocytosis. The eliciting drugs can be identified by positive skin or in vitro tests. The drugs involved in starting the MDH are the same as for DRESS, and they are usually given in rather high doses. Fixed drug combination therapies like sulfamethoxazole/trimethoprim or piperacillin/tazobactam are frequently involved in MDH, and 30-40% of patients with severe DHR to combination therapy show T-cell reactions to both components. The drug-induced T-cell stimulation appears to be due to the p-i mechanism. Importantly, a permanent T-cell activation characterized by PD-1+/CD38+ expression on CD4+/CD25low T cells can be found in the circulation of patients with MDH for many years. In conclusion, MDH is a drug-elicited syndrome characterized by a long-lasting hyperresponsiveness to multiple, structurally unrelated drugs with clinically diverse symptoms.
© 2017 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Drug hypersensitivity; Drug rash with eosinophilia and systemic symptoms; Maculopapular exanthema; Multiple drug hypersensitivity; p-i concept

Mesh:

Year:  2017        PMID: 28315874      PMCID: PMC5472211          DOI: 10.1159/000458725

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  43 in total

1.  Multiple sensitivity to NSAID.

Authors:  R Asero
Journal:  Allergy       Date:  2000-09       Impact factor: 13.146

2.  Sulphasalazine-induced hypersensitivity syndrome: a relapsing disorder and the role of human herpes virus-6.

Authors:  Kirsty Short; Wing-Kin Syn; Geoffrey Haydon
Journal:  Eur J Gastroenterol Hepatol       Date:  2007-02       Impact factor: 2.566

3.  Multiple drug hypersensitivity--proof of multiple drug hypersensitivity by patch and lymphocyte transformation tests.

Authors:  C Gex-Collet; A Helbling; W J Pichler
Journal:  J Investig Allergol Clin Immunol       Date:  2005       Impact factor: 4.333

4.  T-cell reactions to drugs in distinct clinical manifestations of drug allergy.

Authors:  C B Neukomm; N Yawalkar; A Helbling; W J Pichler
Journal:  J Investig Allergol Clin Immunol       Date:  2001       Impact factor: 4.333

5.  Drug hypersensitivity: flare-up reactions, cross-reactivity and multiple drug hypersensitivity.

Authors:  Werner J Pichler; Barbara Daubner; Tom Kawabata
Journal:  J Dermatol       Date:  2011-02-01       Impact factor: 4.005

6.  T cell involvement in cutaneous drug eruptions.

Authors:  Y Hari; K Frutig-Schnyder; M Hurni; N Yawalkar; M P Zanni; B Schnyder; A Kappeler; S von Greyerz; L R Braathen; W J Pichler
Journal:  Clin Exp Allergy       Date:  2001-09       Impact factor: 5.018

7.  Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.

Authors:  Shuen-Iu Hung; Wen-Hung Chung; Zhi-Sheng Liu; Chien-Hsiun Chen; Mo-Song Hsih; Rosaline Chung-yee Hui; Chia-Yu Chu; Yuan-Tsong Chen
Journal:  Pharmacogenomics       Date:  2010-03       Impact factor: 2.533

8.  Multiple-drug intolerance syndrome: clinical findings and usefulness of challenge tests.

Authors:  Domenico Schiavino; Eleonora Nucera; Chiara Roncallo; Emanuela Pollastrini; Tiziana De Pasquale; Carla Lombardo; Giorgia Altomonte; Alessandro Buonomo; Giampiero Patriarca
Journal:  Ann Allergy Asthma Immunol       Date:  2007-08       Impact factor: 6.347

9.  Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism.

Authors:  Bruce R Blazar; Beatriz M Carreno; Angela Panoskaltsis-Mortari; Laura Carter; Yoshiko Iwai; Hideo Yagita; Hiroyuki Nishimura; Patricia A Taylor
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

10.  Flare-up reactions in severe drug hypersensitivity: infection or ongoing T-cell hyperresponsiveness.

Authors:  Lukas Jörg-Walther; Benno Schnyder; Arthur Helbling; Karin Helsing; Alexandra Schüller; Annette Wochner; Werner Pichler
Journal:  Clin Case Rep       Date:  2015-08-26
View more
  19 in total

Review 1.  Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.

Authors:  S Shahzad Mustafa; David Ostrov; Daniel Yerly
Journal:  Curr Allergy Asthma Rep       Date:  2018-03-24       Impact factor: 4.806

2.  Prevalence and characteristics of hospital inpatients with reported fluoroquinolone allergy.

Authors:  Geoffrey C Wall; Matthew J Taylor; Hayden L Smith
Journal:  Int J Clin Pharm       Date:  2018-03-14

3.  Drug-induced hypersensitivity syndrome caused by valproic acid as a monotherapy for epilepsy: First case report in Asian population.

Authors:  X T Wu; P W Hong; D J Suolang; D Zhou; H Stefan
Journal:  Epilepsy Behav Case Rep       Date:  2017-06-20

4.  Spectrum of Cutaneous Adverse Drug Reactions to Anti-tubercular Drugs and Safe Therapy after Re-challenge - A Retrospective Study.

Authors:  Reena K Sharma; Ghanshyam K Verma; Gita Ram Tegta; Samriti Sood; Renu Rattan; Mudita Gupta
Journal:  Indian Dermatol Online J       Date:  2020-03-09

5.  Epidemiology of Severe Cutaneous Adverse Drug Reaction and Its HLA Association among Pediatrics.

Authors:  Hossein Esmaeilzadeh; Shirin Farjadian; Soheila Alyasin; Hamid Nemati; Hesamodin Nabavizadeh; Elmira Esmaeilzadeh
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

6.  Acute Liver Failure in a Patient Treated With Metamizole.

Authors:  Philipp Krisai; Deborah Rudin; David Grünig; Kathrin Scherer; Werner Pichler; Luigi Terracciano; Stephan Krähenbühl
Journal:  Front Pharmacol       Date:  2019-09-11       Impact factor: 5.810

7.  Safety, Efficacy, and Effectiveness of Delabeling in Patients with Multiple Drug Allergy Labels.

Authors:  Chandra Vethody; Roger Yu; Jacob M Keck; Michelle K Onasch; Cosby A Stone; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2020-09-20

8.  Heater Integrated Lab-on-a-Chip Device for Rapid HLA Alleles Amplification towards Prevention of Drug Hypersensitivity.

Authors:  Shah Mukim Uddin; Abkar Sayad; Jianxiong Chan; Duc Hau Huynh; Efstratios Skafidas; Patrick Kwan
Journal:  Sensors (Basel)       Date:  2021-05-13       Impact factor: 3.576

9.  Hydroxychloroquine-induced erythroderma: A rare adverse effect of a commonly used drug.

Authors:  Ananta Khurana; Anusha Katare; Aastha Agarwal; Priyadharshini Kathirvel; Arvind Ahuja
Journal:  Dermatol Ther       Date:  2020-09-08       Impact factor: 3.858

Review 10.  Drug allergy.

Authors:  Richard Warrington; Fanny Silviu-Dan; Tiffany Wong
Journal:  Allergy Asthma Clin Immunol       Date:  2018-09-12       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.